WSCD2 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:9671, HGNC:29117, MIM:619253, NM_001304447, NM_014653, NP_001291376, NP_055468, WSC domain containing 2, WSCD2, XM_017020243, XM_017020244, XM_017020245, XM_017020246, XM_017020247, XM_017020248, XM_017020249, XM_017020250, XM_017020251, XM_017020252, XP_016875732, XP_016875733, XP_016875734, XP_016875735, XP_016875736, XP_016875737, XP_016875738, XP_016875739, XP_016875740, XP_016875741, XR_001748924, XR_001748925, XR_001748926, XR_944841

Id:ENSG00000075035

Entrez:9671

Ensembl:ENSG00000075035

Description:WSC domain sialate O sulfotransferase 2

Predicted to be integral component of membrane. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View WSCD2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with WSCD2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using WSCD2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for WSCD2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with WSCD2.

Results found

Linked to

	Label	Description
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 7 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 10 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE228106 3 V 5 PACLITAXEL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE149880 2 V 1 TAMOXIFEN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE165960 MEK inhibition 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 9 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119369 H10 inhibition 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE238213 dopamine 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 7 v 5 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE195663 cisplatin 0 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE100148 EZH2 inhibition 10 v 5 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE228106 3 V 5 PACLITAXEL HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE149880 2 V 1 TAMOXIFEN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE165960 MEK inhibition 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 9 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE119369 H10 inhibition 3 v 7 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.